ABBV-319: A CD19-Targeting Glucocorticoid Receptor Modulator Antibody-Drug Conjugate Therapy for B Cell Malignancies

ABBV-319 elicited potent glucocorticoid receptor modulator-driven anti-tumor activity against multiple malignant B cell lines in vitro as well as in cell line-derived xenografts and patient-derived xenografts in vivo.